E-LIB Suche - Ergebnisse für: Criseno, Sherwin

1

Discontinuation of long-term growth hormone treatment in ad..:

Criseno, Sherwin ; Gleeson, Helena ; Toogood, Andrew A...
Endocrine Connections. 13 (2024) 5 - p. , 2024

Link: https://doi.org/10.1530/..

2

Diagnostic criteria and proposed management of immune-relat..:

Percik, Ruth ; Criseno, Sherwin ; Adam, Safwaan..
Endocrine Connections. 12 (2023) 5 - p. , 2023

Link: https://doi.org/10.1530/..

3

Endocrine-related adverse conditions in patients receiving ..:

Husebye, Eystein S ; Castinetti, Frederik ; Criseno, Sherwin...
European Journal of Endocrinology. 187 (2022) 6 - p. G1-G21 , 2022

Link: https://doi.org/10.1530/..

4

Contributors:

, In: Pituitary Tumors,

Albani, Adriana ; Albano, Luigi ; Albonette-Felicio, Thiago... - p. xiii-xvi , 2021

Link: https://doi.org/10.1016/..

5

Multidisciplinary team perspective: A model of care for pat..:

, In: Pituitary Tumors,

Fountas, Athanasios ; Hamblin, Ross ; Criseno, Sherwin. - p. 679-685 , 2021

Link: https://doi.org/10.1016/..

6

ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of calciu..:

Gittoes, Neil J ; Criseno, Sherwin ; Appelman-Dijkstra, Natasha M...
European Journal of Endocrinology. 183 (2020) 2 - p. G57-G65 , 2020

Link: https://doi.org/10.1530/..

7

Osteoporosis:

, In: Advanced Practice in Endocrinology Nursing,

Criseno, Sherwin - p. 1005-1035 , 2019

Link: https://doi.org/10.1007/..

8

Glucocorticoid induced adrenal insufficiency is common in s..:

Karangizi, Alvin H. K. ; Al-Shaghana, May ; Logan, Sarah...
BMC Nephrology. 20 (2019) 1 - p. , 2019

Link: https://doi.org/10.1186/..

9

Shared Decision-Making in Growth Hormone Therapy—Implicatio..:

Acerini, Carlo L. ; Segal, David ; Criseno, Sherwin...
Frontiers in Endocrinology. 9 (2018) - p. , 2018

Link: https://doi.org/10.3389/..

10

Mild primary hyperparathyroidism—to treat or not to treat?:

Hassan-Smith, Zaki K ; Criseno, Sherwin ; Gittoes, Neil J L
British Medical Bulletin. 129 (2018) 1 - p. 53-67 , 2018

Link: https://doi.org/10.1093/..

11

Endocrine-related adverse conditions in patients receiving ..:

Husebye, Eystein S ; Castinetti, Frederik ; Criseno, Sherwin...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641795/. , 2022

Link: http://www.ncbi.nlm.nih...

12

Endocrine-related adverse conditions in patients receiving ..:

Husebye, Eystein Sverre ; Castinetti, Frederik ; Criseno, Sherwin...
urn:issn:0804-4643. , 2022

Link: https://hdl.handle.net/1..

13

Endocrine-related adverse conditions in patients receiving ..:

Husebye, Eystein ; Castinetti, Frederik ; Criseno, Sherwin...
info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-22-0689. , 2022

Link: https://amu.hal.science/..

14

Endocrine-related adverse conditions in patients receiving ..:

Husebye, Eystein ; Castinetti, Frederik ; Criseno, Sherwin...
info:eu-repo/semantics/altIdentifier/doi/10.1530/EJE-22-0689. , 2022

Link: https://amu.hal.science/..

15

Endocrinology in the time of COVID-19:Management of calcium..:

Gittoes, Neil J ; Criseno, Sherwin ; Appelman-Dijkstra, Natasha M...
Gittoes , N J , Criseno , S , Appelman-Dijkstra , N M , Bollerslev , J , Canalis , E , Rejnmark , L & Hassan-Smith , Z 2020 , ' Endocrinology in the time of COVID-19 : Management of calcium metabolic disorders and osteoporosis ' , European Journal of Endocrinology , vol. 183 , no. 2 , pp. G57-G65 . https://doi.org/10.1530/EJE-20-0385. , 2020

Link: https://pure.au.dk/porta..